Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cannara BiotechLOVFF -0.67%84 5-Year Yield-on-Cost % is 0.00 as of Jul. 15, 2026. GuruFocus rates LOVFF with a GF Score™ of 84/100 and a GF Value™ of $1.17 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 515 Drug Manufacturers companies, Cannara Biotech ranks worse than 194174.56% on this metric.
Cannara Biotech's yield on cost for the quarter that ended in Feb. 2026 was 0.00.
The historical rank and industry rank for Cannara Biotech's 5-Year Yield-on-Cost % or its related term are showing as below:
LOVFF's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.25 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Cannara Biotech 5-Year Yield-on-Cost % Related Terms
LOVFF vs ZTS, UTHR: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannara Biotech 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Cannara Biotech's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Cannara Biotech is calculated as
Cannara Biotech (LOVFF) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 15, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Cannara Biotech and its competitors. According to the industry distribution chart, Cannara Biotech ranks #999999 out of 515 companies in the Drug Manufacturers industry.
Is Cannara Biotech's 5-Year Yield-on-Cost % too high?
Cannara Biotech's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Cannara Biotech ranks #999999 out of 515 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cannara Biotech has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cannara Biotech ranks #999999 out of 515 companies for 5-Year Yield-on-Cost %. This places Cannara Biotech in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.25, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Cannara Biotech and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannara Biotech's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.17, compared to a current price of $1.33 — trading 13.7% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Cannara Biotech's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cannara Biotech (LOVFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued.
The current stock price of $1.33 is trading 13.7% above its estimated GF Value™ of $1.17.
GuruFocus considers Cannara Biotech to be Modestly Overvalued.
Key valuation signals for LOVFF:
5-Year Yield-on-Cost %: 0.00
GF Value™: $1.17 vs. price of $1.33 (13.7% above fair value)
No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
84GF Score
Get the complete analysis for LOVFF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LOVFF has been successfully added to your 
